| Literature DB >> 25227526 |
Jiang Hu, WeiWei Xiao, ZhiChun He, DeHua Kang, Along Chen, ZhenYu Qi1.
Abstract
BACKGROUND ANDEntities:
Mesh:
Year: 2014 PMID: 25227526 PMCID: PMC4262233 DOI: 10.1186/1748-717X-9-204
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Figure 1Representative planning computed tomography (CT) slices. (A) axial, (C) coronal, (D) sagittal and (B) three dimensional reconstructions. The PTV-G,PTV1 and PTV2 were rendered in blue, purple and red, respectively.
Optimization goals and constraints used for IMRT and RapidArc planning
| Structure | Prescription | Objective | Priority |
|---|---|---|---|
| PTV-G | 70Gy/30F | V95% ≥ 100% | 600 |
| V110% ≤ 10% | 200 | ||
| Dmax < 80Gy | 600 | ||
| PTV1 | 60Gy/30F | V95% ≥ 100% | 600 |
| PTV2 | 50Gy/30F | V95% ≥ 100% | 600 |
| Brain | Dmax < 72Gy | 500 | |
| Dmean: <30Gy and as low as possible | 500 | ||
| V28Gy < 30% | 500 | ||
| Len-Left | Dmax < 10Gy | 200 | |
| Len-Right | Dmax < 10Gy | 200 | |
| Eye-Left | Dmax < 54Gy | 100 | |
| Eye-Right | Dmax < 54Gy | 100 | |
| Optic never-L | Dmax < 55Gy | 100 | |
| Optic nerve-R | Dmax < 55Gy | 100 | |
| Chiasm | Dmax < 55Gy | 100 |
Figure 2Individualized collimator angle for total scalp irradiation. (A) 90°as recommended by Kelly et al. [7]. (B) Splitting target from the middle vertical plane and 50°optimal collimator angle setting.
Dosimetric results for five treatment plans
| Structure | Dosimetry | 3D-CRT | IMRT | sRapidArc | scRapidArc | snRapidArc |
|---|---|---|---|---|---|---|
| PTV-G | V95% (%) | 90.73 | 99.71 | 99.31 | 99.71 | 99.92 |
| V110% (%) | 14.18 | 12.86 | 16.74 | 0.07 | 0.97 | |
| D2% (Gy) | 83.96 | 79.60 | 78.85 | 75.92 | 76.69 | |
| CI | 0.54 | 0.68 | 0.73 | 0.83 | 0.83 | |
| HI | 0.49 | 0.15 | 0.15 | 0.11 | 0.12 | |
| PTV1 | V95% (%) | 86.40 | 100 | 99.99 | 99.50 | 99.72 |
| V110% (%) | 76.76 | 93.51 | 93.83 | 89.77 | 90.54 | |
| D2% (Gy) | 82.39 | 79.23 | 78.73 | 75.80 | 76.53 | |
| CI | 0.43 | 0.45 | 0.47 | 0.54 | 0.54 | |
| HI | 1.13 | 0.22 | 0.21 | 0.21 | 0.21 | |
| PTV2 | V95%(%) | 85.45 | 99.54 | 99.70 | 99.80 | 99.50 |
| V110% (%) | 50.94 | 78.31 | 76.62 | 66.22 | 66.13 | |
| D2% (Gy) | 78.81 | 77.76 | 77.83 | 75.12 | 75.75 | |
| CI | 0.59 | 0.74 | 0.77 | 0.83 | 0.83 | |
| HI | 1.42 | 0.47 | 0.47 | 0.45 | 0.47 | |
| Brain | D1% (Gy) | 69.66 | 68.70 | 66.07 | 62.36 | 62.03 |
| Dmean (Gy) | 23.06 | 28.98 | 25.85 | 21.18 | 19.19 | |
| V5Gy(%) | 91.03 | 100 | 100 | 100 | 100 | |
| V10Gy (%) | 60.98 | 100 | 79.34 | 58.12 | 50.14 | |
| V15Gy (%) | 53.51 | 86.76 | 65.14 | 46.09 | 38.63 | |
| V20Gy (%) | 47.28 | 52.46 | 50.99 | 37.24 | 31.36 | |
| V30Gy (%) | 30.62 | 29.31 | 29.18 | 23.89 | 20.14 | |
| V40Gy (%) | 21.01 | 16.92 | 16.65 | 12.64 | 10.21 | |
| V50Gy (%) | 11.85 | 7.64 | 6.98 | 4.23 | 3.49 | |
| V60Gy (%) | 4.39 | 3.33 | 2.24 | 1.14 | 1.12 | |
| V70Gy (%) | 0.91 | 0.04 | 0 | 0 | 0 | |
| Eye-L | D1% (Gy) | 27.85 | 42.91 | 40.17 | 37.98 | 43.90 |
| Eye-R | D1% (Gy) | 29.96 | 49.11 | 37.13 | 36.23 | 36.43 |
| Len-L | D1% (Gy) | 10.52 | 16.02 | 10.84 | 10.23 | 10.28 |
| Len-R | D1% (Gy) | 10.85 | 16.53 | 10.85 | 10.09 | 10.41 |
| Never-L | D1% (Gy) | 7.10 | 36.82 | 30.16 | 31.06 | 35.38 |
| Never-R | D1% (Gy) | 8.90 | 45.64 | 32.61 | 34.50 | 29.25 |
| Chiasm | D1% (Gy) | 5.20 | 23.10 | 23.16 | 12.82 | 13.87 |
Figure 3An example of brain DVH curves (3D-CRT: black solid line, IMRT: gray solid line, snRapidArc: black dotted line). The protective effectiveness for normal brain tissues was concluded to be snRapidArc > IMRT > 3D-CRT.
Dosimetric verification results for five treatment plans
| 3D-CRT | IMRT | sRapidArc | scRapidArc | snRapidArc | |
|---|---|---|---|---|---|
| Monitor units | 645 | 2832 | 756 | 1022 | 818 |
| Delivery time (s) | 620 | 636 | 156 | 264 | 352 |
| Gamma criteria (%) | / | 98.7 | 99.5 | 98.3 | 96.9 |
Also included were MUs and delivery time of each plan.